894 A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.